There are no approved flaviviral therapies and the development of vaccines against flaviruses has the potential of being undermined by antibody-dependent enhancement(ADE).The flavivirus nonstructural protein 1(NS1)is a promising vaccine antigen with low ADE risk but has yet to be explored as a broad-spectrum therapeutic antibody target.Here,we provide the structural basis of NS1 antibody cross-reactivity through cocrystallization of the antibody 1G5.3 with NS1 proteins from dengue and Zika viruses.
展开▼
机译:Protective Immune Response in BALB/c Mice Induced by the E72-296 Protein of Rubella VirusAU Li, Zhen-Mei Sun, Zi-Hao Wen, Hong-Ling Lin, Bin Chu, Fu-Lu Li, Guo-Hong Wang, Zhi-Yu (zhiyu.wang@sdu.edu.cn)